After its dim third-quarter earnings report on Nov. 2, Moderna (NASDAQ: MRNA) saw its shares crash by more than 12% before recovering. Still, the stock is down by 60% this year, and it's clear that investors continue to have doubts about prospects for the once-vaunted biotech.

But there's more than one reason to believe Moderna may yet have a bright future ahead, provided that you're willing to hold it over the next few years. Let's examine how its strategic plans and favorable stock valuation might make it a great performer for those with a little patience.

Most people are familiar with Moderna thanks to its coronavirus vaccines. It's going to continue making those jabs, but in case it wasn't obvious, peak sales of those vaccinations are in the past and won't be returning.

Continue reading

Source Fool.com